Glibenclamide in aneurysmatic subarachnoid hemorrhage (GASH): study protocol for a randomized controlled trial

Bruno Braga Sisnando da Costa, Isabela Costola Windlin, Edwin Koterba, Vitor Nagai Yamaki, Nícollas Nunes Rabelo, Davi Jorge Fontoura Solla, Manoel Jacobsen Teixeira, Eberval Gadelha Figueiredo, Bruno Braga Sisnando da Costa, Isabela Costola Windlin, Edwin Koterba, Vitor Nagai Yamaki, Nícollas Nunes Rabelo, Davi Jorge Fontoura Solla, Manoel Jacobsen Teixeira, Eberval Gadelha Figueiredo

Abstract

Background: Recent findings on the benefits of glibenclamide as a neuroprotective drug have started a new era for prospective studies on sulfonylureas. The effect of glibenclamide blocking the Sur1-Trpm4 channel was examined in models of subarachnoid hemorrhage and stroke, with findings of significantly reduced tight-junction abnormalities, resulting in less edema formation and considerably reduced transsynaptic apoptosis of hippocampal neurons and significantly ameliorated impairments in spatial learning. Based on these data, we plan a clinical trial to establish evidence of glibenclamide as an adjunct treatment in aneurysmal subarachnoid hemorrhage.

Methods: An estimated 80 patients meeting the inclusion criteria of radiological confirmatory evidence of an aneurysmal subarachnoid hemorrhage, age 18-70 years, and presentation of less than 96 h from the ictus will be allocated randomly into two groups, one receiving 5 mg daily oral intake of glibenclamide for 21 days and another control group receiving a placebo. The study's primary outcome is the modified Rankin scale (mRS) after 6 months, as favorable (mRS 0-2) or unfavorable (mRS 3-6). The secondary outcomes will be late cognitive status, assessed after 6 months by psychological tests (the Short Form Health Survey Questionnaire and the Montreal Cognitive Assessment), as well as death at 6 months, delayed cerebral ischemia and occurrence of serious adverse events due to study medication.

Discussion: There is a growing interest in the scientific community regarding glibenclamide in brain edema and traumatic brain injury, but with very little of this interest targeting spontaneous brain hemorrhage, especially aneurism rupture. Positive outcomes are expected for the treatment patients, especially in language and memory preservation, as has been shown in experimental models.

Trial registration: ClinicalTrials.gov, NCT03569540 . Retrospectively registered on 26 June 2018.

Keywords: Brain aneurysms; Glibenclamide; Subarachnoid hemorrhage.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Schedule of enrolment, interventions, and assessments. WFNS World Federation of Neurological Societies

References

    1. Feigin VL, Lawes CMM, Bennett DA, Barker-callo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 2009;8:355–369. doi: 10.1016/S1474-4422(09)70025-0.
    1. The Across Group Epidemiology of aneurysmal subarachnoid hemorrhage in Australia and New Zealand. Incidence and case fatality from the Australasian Cooperative Research on Subarachnoid Hemorrhage Study (ACROSS) Stroke. 2000;31:1843–1850. doi: 10.1161/01.STR.31.8.1843.
    1. Van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid hemorrhage. Lancet. 2007;369:306–318. doi: 10.1016/S0140-6736(07)60153-6.
    1. Molyneux AJ, Kerr RSC, Yu LM, et al. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomized comparison of effects on survival, dependency, seizures, rebleeding, subgroups and aneurysm occlusion. Lancet. 2005;366:809–817. doi: 10.1016/S0140-6736(05)67214-5.
    1. Macdonald RL. Delayed neurological deterioration after subarachnoid hemorrhage. Nat Rev Neurol. 2014;10:44–58. doi: 10.1038/nrneurol.2013.246.
    1. Macdonald RL, Higashida RT, Keller E, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping: a randomized, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2) Lancet Neurol. 2011;10:618–625. doi: 10.1016/S1474-4422(11)70108-9.
    1. Van den bergh W. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke. 2005;36:1011–1015. doi: 10.1161/01.STR.0000160801.96998.57.
    1. Shaw MDM, Vermeulen M, Murray GD, Pickard JD, Bell BA, Teasdale GM. Efficacy and safety of the endothelinA/B receptor antagonist TAK-044 in treating subarachnoid hemorrhage: a report by the Steering Committee on behalf of the UK/Netherlands/Eire TAK-044 subarachnoid hemorrhage study group. J Neurosurg. 2000;93:992–997. doi: 10.3171/jns.2000.93.6.0992.
    1. Siasios Ioannis, Kapsalaki Eftychia Z., Fountas Kostas N. Cerebral Vasospasm Pharmacological Treatment: An Update. Neurology Research International. 2013;2013:1–20. doi: 10.1155/2013/571328.
    1. Haley EC, Kassel NF, Apperson-hansen C, Maile MH, Alves WM. A randomised double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America. J Neurosurg. 1997;86:467–474. doi: 10.3171/jns.1997.86.3.0467.
    1. Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid hemorrhage: British aneurysm nimodipine trial. BMJ. 1989;298:636–642. doi: 10.1136/bmj.298.6674.636.
    1. Van gijn J, Rinkel GJE. Subarachnoid hemorrhage: diagnosis, causes and management. Brain. 2001;124:249–278. doi: 10.1093/brain/124.2.249.
    1. Dhar R, Diringer M. Statins and anti-inflammatory therapies for subarachnoid hemorrhage. Curr Treat Options Neurol. 2012;14:164–174. doi: 10.1007/s11940-012-0163-z.
    1. Tseng MY, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage. A phase 11 randomised placebo-controlled trial. Stroke. 2005;36:1627–1632. doi: 10.1161/01.STR.0000176743.67564.5d.
    1. Tseng MY, Hutchinson PJA, Turner CL, et al. Biological effects of acute pravastatin treatment in patients after aneurysmal subarachnoid hemorrhage: a double-blind placebo-controlled trial. J Neurosurg. 2007;107:1092–1100. doi: 10.3171/JNS-07/12/1092.
    1. Kurland DB, Tosun C, Pampori A, Karimy JK, Caffes NM, Gerzanich V, Simard JM. Glibenclamide for the treatment of acute CNS injury. Pharmaceuticals (Basel) 2013;6(10):1287–1303. doi: 10.3390/ph6101287.
    1. Kunte HL, Schmidt S, Eliasziw M, Del zoppo GJ, Simard JM, Masuhr F, Weih M, Dirnagl U. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke. 2007;38(9):2526–2530. doi: 10.1161/STROKEAHA.107.482216.
    1. Tosun C, Kurland DB, Mehta R, Castellani RJ, Dejong JL, Kwon MS, Woo SK, Gerzanich V, Simard JM. Inhibition of the Sur1-Trpm4 channel reduces neuroinflammation and cognitive impairment in subarachnoid hemorrhage. Stroke. 2013;44(12):3522–3528. doi: 10.1161/STROKEAHA.113.002904.
    1. Simard JM, Geng Z, Woo SK, Ivanova S, Tosun C, Melnichenko L, Gerzanich V. Glibenclamide reduces inflammation, vasogenic edema, and caspase-3 activation after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2013;29:317–330. doi: 10.1038/jcbfm.2008.120.
    1. Eisenberg E, Banshal V. Glyburide (RP-1127) for traumatic brain injury (TBI). Available from: . Accessed 6 May 2015.
    1. Sheth KN, Kimberly WT. Safety study of RP-1127 (glyburide for injection) in healthy volunteers. Available from: . Accessed 4 June 2014.
    1. Sheth KN, Kimberly WT. Glyburide advantage in malignant edema and stroke-remedy pharmaceuticals (GAMES-RP). Available from: . Accessed 2 June 2015.
    1. Sheth KN. Glyburide advantage in malignant edema and stroke pilot (GAMES-PILOT). Available from: . Accessed 6 June 2014.
    1. Jiang B, Li L, Chen Q, Tao Y, Yang L, Zhang B, Zhang JH, Feng H, Chen Z, Tang J, Zhu G. Role of glibenclamide in brain injury after intracerebral hemorrhage. Transl Stroke Res. 2017;8:183–193. doi: 10.1007/s12975-016-0506-2.
    1. Vergouwen MDI, Vermeulen M, van Gijn J, Rinkel GJE, Wijdicks EF, Muizelaar JP, Mendelow AD, Juvela S, Yonas H, Terbrugge KG, Macdonald RL, Diringer MN, Broderick JP, Dreier JP, Roos YBWEM. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41(10):2391–2395. doi: 10.1161/STROKEAHA.110.589275.
    1. Patel AD, Gerzanich V, Geng Z, Simard JM. Glibenclamide reduces hippocampal injury and preserves rapid spatial learning in a model of traumatic brain injury. J Neuropathol Exp Neurol. 2010;69:1177–1190. doi: 10.1097/NEN.0b013e3181fbf6d6.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다